详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

GREM1 may be a biological indicator and potential target of bladder cancer

10| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Pathology, Ningbo Clinical Pathology Diagnosis Center, Ningbo, 315211, Zhejiang, China. [2]Department of Pathology, Taizhou Hospital, Wenzhou Medical University, Linhai, 317000, Zhejiang, China. [3]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.

出处：

DOI：

关键词： GREM1 Bladder cancer Immune Biomarker

摘要：

Gremlin 1 (GREM1) can regulate the development of many cancers. However, a few studies have revealed the role of GREM1 in bladder cancer (BC). To evaluate the expression and potential function of GREM1 in bladder cancer, we used R version 3.6.3 and related packages to analyze the data from common databases. Samples from our institution were assessed by immunohistochemical staining (IHC), which was approved by the Institutional Ethics Committee (K20220830). GREM1 was highly expressed in BC tissues according to the TCGA and IHC data. Data from TCGA, GSE31684, GSE32894, and IHC showed that GREM1 has significant prognostic value for BC patients. GREM1 is involved in immune and metabolism-related pathways. According to the TIDE algorithm, 61.0% of patients with low GREM1 expression responded well to immunotherapy, compared to only 13.3% in the high GREM1 expression group. High GREM1 expression was associated with sensitivity to cisplatin, docetaxel, gemcitabine, and vinblastine. Thus, GREM1 can predict prognosis and responses to immunotherapy and chemotherapy in BC patients, making it a potential biomarker and therapeutic target.© 2024. The Author(s).

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 3 区综合性期刊

小类 | 3 区综合性期刊

最新[2025]版：

大类 | 3 区综合性期刊

小类 | 3 区综合性期刊

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q1 MULTIDISCIPLINARY SCIENCES

影响因子： 3.8 最新[2023版] 4.3 最新五年平均 3.8 出版当年[2023版] 0 出版当年五年平均 3.8 出版前一年[2023版]

第一作者：

第一作者机构： [1]Department of Pathology, Ningbo Clinical Pathology Diagnosis Center, Ningbo, 315211, Zhejiang, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]HSD17B1 could serve as a prognostic biomarker for bladder cancer patients [2]DMRT1 could serve as a prognostic biomarker for bladder cancer patients [3]The Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Bladder Cancer. [4]CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer [5]IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer [6]Transmembrane protein 132A (TMEM132A) predicts overall survival for bladder cancer patients [7]Identification of endothelial-related molecular subtypes for bladder cancer patients [8]Prediction of immunotherapy response of bladder cancer with a pyroptosis-related signature indicating tumor immune microenvironment [9]ENPEP as a potential predictor of immune checkpoint inhibitor efficacy. [10]Programmed death-ligand 2 (PD-L2) expression in bladder cancer.